In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method

Cancer Gene Therapy

Volumn 15, Issue 8, 2008, Pages 508-516

  Yu, S S ^a   Nukaya, I ^a   Enoki, T ^b   Chatani, E ^a   Kato, A ^b   Goto, Y ^a   Dan, K ^a   Sasaki, M ^a   Tomita, K ^b   Tanabe, M ^b   Chono, H ^a   Mineno, J ^a   Kato, I ^b  

^a TAKARA BIO INC   (Japan)

^b Biotechnology Research Laboratories   (Japan)

Author keywords

Adoptive T cell transfer therapy; Fibronectin CH296 stimulation; In vivo persistence; Naive T cells; Retroviral gene therapy

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FIBRONECTIN; FIBRONECTIN CH296; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; RECOMBINANT PROTEIN; RETRONECTIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4 CD8 RATIO; CELL PROLIFERATION; CELL TRANSPLANTATION; CONJUGATION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; SCID MOUSE; T LYMPHOCYTE ACTIVATION; TECHNIQUE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BASE SEQUENCE; CELL TRANSPLANTATION; DNA PRIMERS; FIBRONECTINS; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, SCID; PEPTIDE FRAGMENTS; RETROVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

MUS;

EID: 48249092770     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.21     Document Type: Article

References (27)

1. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117: 1204-1212.
2. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99: 16168-16173.
3. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
4. Hombach A, Heuser C, Abken H. The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther 2002; 2: 211-226.
5. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512-519.
6. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
7. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
8. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626.
9. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173: 7125-7130.
10. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28: 258-267.
11. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175: 7046-7052.
12. Yoder MC, Williams DA. Matrix molecule interactions with hematopoietic stem cells. Exp Hematol 1995; 23: 961-967.
13. Ruoslahti E. Fibronectin and its receptors. Annu Rev Biochem 1988; 57: 375-413.
14. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
15. Nojima Y, Humphries MJ, Mould AP, Komoriya A, Yamada KM, Schlossman SF et al. VLA-4 mediates CD3-dependent CD4+ T cell activation via the CS1 alternatively spliced domain of fibronectin. J Exp Med 1990; 172: 1185-1192.
16. Nojima Y, Rothstein DM, Sugita K, Schlossman SF, Morimoto C. Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein. J Exp Med 1992; 175: 1045-1053.
17. Sato T, Tachibana K, Nojima Y, D'Avirro N, Morimoto C. Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J I mmunol 1995; 155: 2938-2947.
18. Kimizuka F, Taguchi Y, Ohdate Y, Kawase Y, Shimojo T, Hashino K et al. Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. J Biochem (Tokyo) 1991; 110: 284-291.
19. Muraki N, Ideno M, Nukaya I, Sagawa H, Enoki T, Kato I. T cell expansion using RetroNectin (I): useful method to expand T cells, characterized by high portion of naive T-like cells. Sixty-Fifth Annual Meeting of the Japanese Cancer Association; 29 September 2006; Yokohama, Kanagawa. Japanese Cancer Association: Shinjuku, Tokyo, 2006.
20. Ideno M, Muraki N, Nukaya I, Sagawa H, Enoki T, Kato I. T cell expansion using RetroNectin (II): RN-T cells contain high portion of naïve T-like cells and show high ability of antigen recognition. Sixty-Fifth Annual Meeting of the Japanese Cancer Association; 29 September 2006; Yokohama, Kanagawa. Japanese Cancer Association: Shinjuku, Tokyo, 2006.
21. Yu SS, Kim JM, Kim S. High efficiency retroviral vectors that contain no viral coding sequences. Gene Therapy 2000; 7: 797-804.
22. Hong Y, Yu SS, Kim JM, Lee K, Na YS, Whitley CB et al. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome. J Gene Med 2003; 5: 18-29.
23. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4: 225-234.
24. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE et al. Central memory self/ tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102: 9571-9576.
25. Dardalhon V, Jaleco S, Rebouissou C, Ferrand C, Skander N, Swainson L et al. Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector. Blood 2000; 96: 885-893.
26. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
27. Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997; 159: 5921-5930.